Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PGEN Stock Forecast 2025-2026
$1.49
Current Price
$419.16M
Market Cap
Buy 3
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to PGEN Price Targets
+320.1%
To High Target of $6.26
+311.4%
To Median Target of $6.13
+302.7%
To Low Target of $6.00
PGEN Price Momentum
-2.0%
1 Week Change
+5.7%
1 Month Change
-2.6%
1 Year Change
+33.0%
Year-to-Date Change
-31.3%
From 52W High of $2.17
+129.2%
From 52W Low of $0.65
📊 TOP ANALYST CALLS
Did PGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Precigen is one of their latest high-conviction picks.
Latest PGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, PGEN has a bullish consensus with a median price target of $6.13 (ranging from $6.00 to $6.26). The overall analyst rating is Buy (7.5/10). Currently trading at $1.49, the median forecast implies a 311.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Jason Butler at JMP Securities, suggesting a 302.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGEN Analyst Ratings
3
Buy
0
Hold
1
Sell
PGEN Price Target Range
Low
$6.00
Average
$6.13
High
$6.26
Current: $1.49
Latest PGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 12, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $6.00 |
| May 15, 2025 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Mar 20, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $6.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jan 14, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $5.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $4.00 |
| Aug 15, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $7.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $4.00 |
| Jun 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Jun 3, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $10.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| May 15, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
| May 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| May 15, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $7.00 |
| Mar 22, 2024 | JP Morgan | Brian Cheng | Underweight | Downgrade | $0.00 |
| Mar 20, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
Precigen Inc. (PGEN) Competitors
The following stocks are similar to Precigen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Precigen Inc. (PGEN) Financial Data
Precigen Inc. has a market capitalization of $419.16M with a P/E ratio of -3.2x. The company generates $4.20M in trailing twelve-month revenue with a -8.7% profit margin.
Revenue growth is +25.9% quarter-over-quarter, while maintaining an operating margin of -1,685.0% and return on equity of -278.5%.
Valuation Metrics
Market Cap
$419.16M
Enterprise Value
$373.85M
P/E Ratio
-3.2x
PEG Ratio
-6.5x
Price/Sales
99.8x
Growth & Margins
Revenue Growth (YoY)
+25.9%
Gross Margin
+18.0%
Operating Margin
-1,685.0%
Net Margin
-8.7%
EPS Growth
+25.9%
Financial Health
Cash/Price Ratio
+18.3%
Current Ratio
3.5x
Debt/Equity
35.0x
ROE
-278.5%
ROA
-44.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Precigen Inc. (PGEN) Business Model
About Precigen Inc.
What They Do
Develops innovative gene therapies for diseases.
Business Model
The company operates by leveraging its proprietary UltraCAR-T platform to engineer T-cells that enhance immune responses against cancer. It generates revenue through collaborations, licensing agreements, and potential commercialization of its gene therapy products targeting cancer, autoimmune disorders, and infectious diseases.
Additional Information
Precigen Inc. is headquartered in Germantown, Maryland, and is focused on advancing personalized medicine and precision therapies to meet unmet medical needs. The company is a key player in the biopharmaceutical sector, contributing to transformative research efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
143
CEO
Dr. Helen Sabzevari MPH, Ph.D.
Country
United States
IPO Year
2019
Website
precigen.comPrecigen Inc. (PGEN) Latest News & Analysis
Latest News
Quick Summary
Precigen's BLA for PRGN-2012, targeting RRP, is under FDA priority review, with a decision expected by August 27, 2025. The company has $81M to support operations into 2026.
Why It Matters
PRGN-2012's potential FDA approval and anticipated launch could significantly boost Precigen's market position and revenue, impacting stock performance and investor sentiment positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Precigen, Inc. will co-host RRP Awareness Day on June 11, 2025, to raise awareness about recurrent respiratory papillomatosis, a chronic disease with no FDA-approved treatment.
Why It Matters
The collaboration between Precigen and the RRPF highlights potential market opportunities in treating RRP, a condition lacking FDA-approved therapies, signaling possible future revenue streams for the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Precigen, Inc. will hold its Q4 2024 earnings conference call on March 19, 2025, at 4:30 PM ET, featuring key executives and analysts from various financial institutions.
Why It Matters
The upcoming earnings call will provide insights into Precigen's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
FDA granted priority review for Precigen's PRGN-2012, targeting a PDUFA date of August 27, 2025. The company had $97.9M in cash at year-end 2024, supporting a commercial launch.
Why It Matters
The FDA's priority review and positive clinical results for PRGN-2012 enhance Precigen's market potential, while solid cash reserves support operations through the anticipated 2025 launch, boosting investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Precigen, Inc. (PGEN) reported a quarterly loss of $0.04 per share, better than the estimated loss of $0.06, and improved from a loss of $0.09 per share a year earlier.
Why It Matters
Precigen's smaller quarterly loss than expected indicates improving financial performance, potentially boosting investor confidence and attracting interest in the stock.
Source: Zacks Investment Research
Market Sentiment:
Negative
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
3 months ago
Quick Summary
Precigen, Inc. (Nasdaq: PGEN) will release its full year 2024 financial results and business updates on March 19, 2025.
Why It Matters
Precigen's upcoming financial results and business updates can influence stock performance, investor sentiment, and market expectations about its growth and innovation potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PGEN Stock
What is Precigen Inc.'s (PGEN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Precigen Inc. (PGEN) has a median price target of $6.13. The highest price target is $6.26 and the lowest is $6.00.
Is PGEN stock a good investment in 2025?
According to current analyst ratings, PGEN has 3 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PGEN stock?
Wall Street analysts predict PGEN stock could reach $6.13 in the next 12 months. This represents a 311.4% increase from the current price of $1.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precigen Inc.'s business model?
The company operates by leveraging its proprietary UltraCAR-T platform to engineer T-cells that enhance immune responses against cancer. It generates revenue through collaborations, licensing agreements, and potential commercialization of its gene therapy products targeting cancer, autoimmune disorders, and infectious diseases.
What is the highest forecasted price for PGEN Precigen Inc.?
The highest price target for PGEN is $6.26 from at , which represents a 320.1% increase from the current price of $1.49.
What is the lowest forecasted price for PGEN Precigen Inc.?
The lowest price target for PGEN is $6.00 from Jason Butler at JMP Securities, which represents a 302.7% increase from the current price of $1.49.
What is the overall PGEN consensus from analysts for Precigen Inc.?
The overall analyst consensus for PGEN is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $6.13.
How accurate are PGEN stock price projections?
Stock price projections, including those for Precigen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 9:44 AM UTC